Is Meta Stock a Buy After Its AI Spending Spree? — Positive
META The Motley Fool — December 02, 2025Meta Platforms is aggressively investing in building artificial intelligence (AI) data center capacity ahead of demand. Despite heavy AI investments, Meta is delivering impressive revenue and operating income.
Citizens, Inc. Announces Plans for Upcoming Investor Conferences — Neutral
CIA Newsfile Corp — December 02, 2025Sidoti Virtual Conference on December 10 and 11, 2025 Emerging Growth Virtual Conference on December 11, 2025 Austin, Texas--(Newsfile Corp. - December 2, 2025) - Citizens, Inc. (NYSE: CIA), a leading diversified financial services company specializing in life, living benefits, and final expense insurance, today provided additional information related to its previously announced participation in upcoming investor conferences. Sidoti Virtual Conference on December 10 and 11, 2025 Citizens management plans to participate in the Sidoti Virtual Conference on December 10 and 11.
Select Water Solutions: Water Infrastructure Outshines Completion Weakness — Negative
WTTR Seeking Alpha — December 02, 2025Select Water Solutions remains a Buy despite recent underperformance, driven by long-term demand for water midstream solutions in the Permian Basin. WTTR's integrated recycling and dual-pipeline infrastructure, plus a new lithium-extraction project, are set to fuel multiyear growth and revenue diversification. Short-term pressures include negative free cash flow from elevated capex and softer completions activity, but liquidity and debt remain manageable.
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension — Neutral
AZN Business Wire — December 02, 2025WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure. The Prescription Drug User Fee Act (PDUFA) date is anticipated during the second quarter of 202.
Starbucks: Over-Caffeinated Valuation, Foamy Dividend Safety - Sell — Neutral
SBUX Seeking Alpha — December 02, 2025Starbucks (SBUX) is rated a sell due to ongoing margin pressure, weak earnings, and an unattractive risk/reward profile despite operational improvements. SBUX posted its first positive global comp in seven quarters, but operating margins collapsed to 9.4% and EPS declined, with the dividend barely covered. Competitive pressures in China and the U.S., high coffee costs, and a premium valuation (35x trailing earnings) further challenge the turnaround story.
Vertiv: The Most Reliable AI Infrastructure Bet In A Crowded Market — Positive
VRT Seeking Alpha — December 02, 2025Vertiv Holdings (VRT) is a compelling buy, leveraging its leadership in liquid cooling and power solutions for data centers amid AI-driven secular growth. VRT's moat is reinforced by high integration costs, sticky contracts, and robust order book visibility, with a $9.5B backlog nearly matching annual revenue. Operating margins are expanding, with a 25% target by 2029, and VRT's strong balance sheet supports both organic growth and strategic acquisitions.
NVIDIA's Q3 Data Center Sales Soar 56%: Can NVDA Sustain the Momentum? — Positive
NVDA Zacks Investment Research — December 02, 2025NVDA's data center sales hit $51.22B as surging AI demand fuels record growth and expectations for a strong Q4.
Can CRDO Tap a $10B+ Market With Record Q2 & New Growth Pillars? — Positive
CRDO Zacks Investment Research — December 02, 2025Credo surges on record revenue growth as AI demand and new pillars like ZF optics, ALCs and OmniConnect gearboxes expand its multibillion-dollar reach.
United Natural Foods (UNFI) Surpasses Q1 Earnings Estimates — Positive
UNFI Zacks Investment Research — December 02, 2025United Natural Foods (UNFI) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.16 per share a year ago.
IP Strategy Publishes Monthly Validator & Ecosystem Update (November 2025) — Neutral
IPST GlobeNewsWire — December 02, 2025GIG HARBOR, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- IP Strategy (Nasdaq: IPST) (the “Company”), the first company to adopt a treasury reserve policy centered on the $IP token, releases its monthly publication detailing its validator business performance and broader ecosystem developments for tokenized intellectual property and AI-native data networks.
Cycurion, Inc. Awarded Statewide Management Consulting Services Term Contract by the Florida Department of Management Services — Neutral
CYCU GlobeNewsWire — December 02, 2025MCLEAN, Va., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. ("Cycurion" or the "Company") (NASDAQ: CYCU), a publicly traded leader in technology and staffing solutions for the public sector, is proud to announce that it has been officially awarded a position on the State of Florida's Management Consulting Services State Term Contract, as outlined in RFP No.
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 — Neutral
CELZ GlobeNewsWire — December 02, 2025Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets
Palantir stock price at risk of a crash as valuation concerns persist — Negative
PLTR Invezz — December 02, 2025Palantir stock price has dropped into a local bear market after falling by ~20% from its highest point this year. PLTR was trading at $167, down from the year-to-date high of $207.
Edible Garden to Feature Hydroponic Basil, Pulp, and Pickle Party® at the NY Produce Show at the Jacob Javits Center in New York City on December 3 — Neutral
EDBL GlobeNewsWire — December 02, 2025Company's Operational Excellence and Growing Brand Portfolio Continue to Drive Leadership in the Highly Competitive NY Metropolitan Market Company's Operational Excellence and Growing Brand Portfolio Continue to Drive Leadership in the Highly Competitive NY Metropolitan Market
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding — Neutral
INCY Business Wire — December 02, 2025WILMINGTON, Del.--(BUSINESS WIRE)--Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding.
Jamf Partners With UberEther to Accelerate FedRAMP High and DoD IL5 Authorization — Neutral
JAMF Business Wire — December 02, 2025MINNEAPOLIS--(BUSINESS WIRE)--Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, today announced its intent to achieve FedRAMP High and DoD IL5 authorization for United States public sector and commercial organizations requiring best-in-class security requirements. To accelerate this effort, Jamf has entered a strategic partnership with UberEther, a leading provider of hyper secure cloud environments for government and regulated industries. This collaboration accelerates.
Lumen Renews Signature Teachers & Technology Grant Program with $1 Million for Classroom Innovation — Neutral
LUMN Business Wire — December 02, 2025DENVER--(BUSINESS WIRE)--Lumen Technologies (NYSE: LUMN) today announced the latest round of its long-standing Teachers and Technology grant program, committing $1 million in new funding to help K-12 educators bring innovative technology into their classrooms. Through the Lumen Clarke M. Williams Foundation, individual grants of up to $5,000 will be awarded to schools in 10 states to purchase technology that equips students with the digital skills needed for success today and in an AI-driven fu.
ASP Isotopes Inc. Announces Paul Mann to Return from Temporary Leave of Absence as Executive Chairman and Chief Executive Officer — Neutral
ASPI GlobeNewsWire — December 02, 2025WASHINGTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that, effective January 19, 2026, Paul Mann, the founder and Executive Chairman of ASP Isotopes, will resume his role as the Company's Chief Executive Officer and continue as Executive Chairman.
Hyundai Motor America Donates 18 Electric Vehicles to Universal Technical Institute — Neutral
UTI PRNewsWire — December 02, 2025IONIQ 5 SUVs to be used in programs nationwide. PHOENIX , Dec. 2, 2025 /PRNewswire/ -- Universal Technical Institute (UTI), the transportation, skilled trades, electrical and energy education division Universal Technical Institute, Inc., today announced that Hyundai Motor America has donated 18 electric vehicles for use at UTI campuses nationwide.
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging — Neutral
LGVN GlobeNewsWire — December 02, 2025The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dilated cardiomyopathy Non-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, often leading to heart transplantation No approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight loss Laromestrocel, a mesenchymal stem cell therapy, has delivered positive initial results across two clinical trials in aging-related frailty MIAMI, Dec. …